Vertex Pharmaceuticals (VRTX) Non-Current Debt (2009 - 2016)

Vertex Pharmaceuticals' Non-Current Debt history runs 6 years deep, the most recent figure standing at $74.9 million for Q2 2016.

• In Q2 2016, Non-Current Debt fell 70.26% year-over-year to $74.9 million; the TTM figure through Jun 2016 stood at $74.9 million (down 70.26% YoY), while the FY2015 annual figure was $223.9 million, down 20.21% from the prior year.
• Non-Current Debt for Q2 2016 stood at $74.9 million, down from $149.6 million in the prior quarter.
• The five-year high for Non-Current Debt was $294.8 million in Q3 2015, with the low at $74.9 million in Q2 2016.
• The 3-year median for Non-Current Debt is $259.1 million (2015), against an average of $229.6 million.
• The sharpest annual moves came in 2015 and 2016: Non-Current Debt climbed 0.03% in 2015, then slumped 70.26% in 2016.
• Vertex Pharmaceuticals' Non-Current Debt stood at $280.6 million in 2014, then fell by 20.21% to $223.9 million in 2015, then plunged by 66.53% to $74.9 million in 2016.
• Business Quant data shows VRTX's Non-Current Debt at $74.9 million in Q2 2016, $149.6 million in Q1 2016, and $223.9 million in Q4 2015.